Dr. Reddy's received Health Canada approval for its generic Semaglutide Injection, authorizing its sale in Canada.
The company is the first to receive marketing authorization for generic Semaglutide Injection in Canada.
The approval covers two dosage strengths and leverages the company's in-house API and peptide development capabilities.
Canada is the world's second-largest market for Semaglutide, with nearly 3.9 million people diagnosed with diabetes.